Replenishment of GDF11 Reverses Cardiac Hypertrophy in Aging Animals
|
By LabMedica International staff writers Posted on 22 May 2013 |

Image: Senior author Dr. Richard Lee (left) with contributing author Dr. Amy J. Wagers (right) (Photo courtesy of Harvard University).
Experimental data collected by a team of cardiovascular disease researchers identified the decline in levels of the blood-borne protein growth differentiation factor 11 (GDF11) as contributing to deterioration of the heart muscle (cardiac hypertrophy) that occurs with advanced age and showed that restoration of GDF11 could reverse this process.
Investigators at Harvard University (Boston, MA, USA) searched for factors leading to the development of cardiac hypertrophy by using heterochronic parabiosis, a surgical technique in which joining of animals of different ages leads to a shared circulation.
The circulatory systems of old and young mice were surgically joined. After four weeks of exposure to the circulation of young mice, indicators of cardiac hypertrophy in old mice dramatically regressed. Changes included reduced cardiomyocyte size and molecular remodeling. This reversal of age-related hypertrophy was not attributable to hemodynamic or behavioral effects of the parabiosis procedure, implicating a blood-borne factor.
The investigators used modified aptamer-based proteomics to identify the TGF-beta superfamily member GDF11 as a circulating factor in young mice that declined with age. Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications.
GDF11 is a member of the bone morphogenetic protein (BMP) family and the TGF-beta (transforming growth factor beta) superfamily. This group of proteins is characterized by a polybasic proteolytic processing site, which is cleaved to produce a mature protein containing seven conserved cysteine residues. The members of this family are regulators of cell growth and differentiation in both embryonic and adult tissues. Studies in animals suggest that this protein is involved in mesodermal formation and neurogenesis during embryonic development.
Results published in the May 9, 2013, online edition of the journal Cell revealed that treatment of old mice that restored GDF11 to youthful levels replicated the effects of parabiosis by reversing age-related hypertrophy, a finding that implies a possible therapeutic use for this protein in geriatric medicine.
"There has been evidence that circulating bloodstream factors exist in mammals that can rejuvenate tissues, but they have not been identified. This study found the first factor like this," said senior study author Dr. Richard Lee, professor of medicine at Harvard University.
Related Links:
Harvard University
Investigators at Harvard University (Boston, MA, USA) searched for factors leading to the development of cardiac hypertrophy by using heterochronic parabiosis, a surgical technique in which joining of animals of different ages leads to a shared circulation.
The circulatory systems of old and young mice were surgically joined. After four weeks of exposure to the circulation of young mice, indicators of cardiac hypertrophy in old mice dramatically regressed. Changes included reduced cardiomyocyte size and molecular remodeling. This reversal of age-related hypertrophy was not attributable to hemodynamic or behavioral effects of the parabiosis procedure, implicating a blood-borne factor.
The investigators used modified aptamer-based proteomics to identify the TGF-beta superfamily member GDF11 as a circulating factor in young mice that declined with age. Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications.
GDF11 is a member of the bone morphogenetic protein (BMP) family and the TGF-beta (transforming growth factor beta) superfamily. This group of proteins is characterized by a polybasic proteolytic processing site, which is cleaved to produce a mature protein containing seven conserved cysteine residues. The members of this family are regulators of cell growth and differentiation in both embryonic and adult tissues. Studies in animals suggest that this protein is involved in mesodermal formation and neurogenesis during embryonic development.
Results published in the May 9, 2013, online edition of the journal Cell revealed that treatment of old mice that restored GDF11 to youthful levels replicated the effects of parabiosis by reversing age-related hypertrophy, a finding that implies a possible therapeutic use for this protein in geriatric medicine.
"There has been evidence that circulating bloodstream factors exist in mammals that can rejuvenate tissues, but they have not been identified. This study found the first factor like this," said senior study author Dr. Richard Lee, professor of medicine at Harvard University.
Related Links:
Harvard University
Latest BioResearch News
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Dementia in Women 25 Years Before Symptoms Begin
Dementia and Alzheimer’s disease often develop silently over many years before symptoms appear. Detecting risk earlier could allow preventive strategies to begin long before memory problems interfere with... Read more
Serial Liquid Biopsies Reveal Therapy Resistance in Metastatic Prostate Cancer
Metastatic Prostate cancer can rapidly adapt under treatment, making it difficult to detect resistance before clinical progression. Genomic results from archival tumor tissue may no longer reflect the... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more








